对胰腺癌分子标和针对性治疗的临床试验的更新
Rachael A Safyan1, E Gabriela Chiorean1
1University of Washington School of Medicine, Seattle, WA, USA; Fred Hutchinson Cancer Center, Seattle, WA, USA.
Surgical oncology
|July 26, 2025
概括
精准医学为胰腺癌患者提供了新的希望,因为它针对特定的分子变化. 本综述强调了关键的基因突变和新兴疗法,以个性化治疗胰腺管道腺癌.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 胰腺管道腺癌 (PDA) 是一种具有高度攻击性的癌症,治疗选择有限.
- 了解分子异质性对于开发个性化治疗策略至关重要.
研究的目的:
- 审查PDA中临床相关的分子变化.
- 突出针对性疗法和正在进行的临床试验,以改善患者的治疗结果.
主要方法:
- 关于PDA分子变化的文献综述.
- 针对性疗法和FDA批准的治疗方法的分析.
- 对新药正在进行的临床试验的概述.
主要成果:
- KRAS突变很普遍 (90%),特定的抑制剂显示出有前途.
- 克拉斯野生型PDA为EGFR封锁提供了机会.
- 像MSI-High,BRAF V600E,HER2放大和基因融合这样的罕见变化是可针对的.
- 向治疗和免疫检查点抑制剂提供了新的治疗途径.
结论:
- 专注于分子点的个性化医疗方法对于推进PDA治疗至关重要.
- 识别特定突变可以应用向疗法,从而有可能改善患者的生存率和结果.
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Targets for Drug Action: Overview
7.4K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.4K


